期刊文献+

尼莫地平干乳的家兔口服生物利用度研究 被引量:1

Studies on the oral bioavailability of the nimodipine dried emulsion in rabbits
在线阅读 下载PDF
导出
摘要 目的以尼莫地平为模型药物,对其干乳、脂肪乳、片剂3种制剂的生物利用度进行比较研究。方法新西兰大白兔单次口饲尼莫地平制剂,用HPLC法测定血浆中尼莫地平的浓度,根据血药浓度计算生物利用度。结果兔口饲尼莫地平后,干乳和脂肪乳的生物利用度均大于片剂,差异具有统计学意义;干乳和脂肪乳的生物利用度比较,差异无统计学意义。与片剂相比尼莫地平干乳和脂肪乳均具有一定的缓释作用。结论干乳和脂肪乳能较大地提高尼莫地平兔口服生物利用度,且具有缓释作用。 Objective To study the oral bioavailability of the nimodipine dried emulsion. Methods HPLC was used to determine the blood concentrations of nimodipine after the dried emulsion, emulsion and tablets of nimodipine were orally administrated to the rabbit respectively. Results The bioavailabilities were ranked as follws : emulsion 〉 dried emulsion 〉 tablet. The difference of the bioavailabilities between dried emulsion and tablet was significant( P 〈 0. 05 ). The difference of the bioavailabilities between emulsion and tablet was also significant( P 〈 0.05). The difference of the bioavailabilities between dried emulsion and emulsion was not significant (P 〉 0.05 ). Conclusion The results showed that the emulsion and dried emulsion of nimodipine could markedly increase the oral absorption of the drug. Conclusion With the nimodipine tablet, the emulsion and dried emulsion have sustained release effect.
出处 《中国实用医药》 2009年第3期3-5,共3页 China Practical Medicine
关键词 尼莫地平 干乳 脂肪乳 生物利用度 HPLC Nimodipine Dried emulsion Bioavailability HPLC
  • 相关文献

参考文献2

共引文献4

同被引文献19

  • 1岳鹏飞,袁海龙,杨明,游荣辉,朱卫丰,肖小河.葛根素亚微乳的制备及表征[J].药学学报,2007,42(6):649-655. 被引量:12
  • 2Mac F J. The development of fat emulsions [J]. Nutrition, 1999, 15(7/8): 641-645.
  • 3Shi S, Chen H, Cui Y, et al. Formulation, stability and degradation kinetics of intravenous cinnarizine lipid emulsion [J]. Int J Pharm, 2009, 373: 147-155.
  • 4Zhao D, Gong T, Fu Y, et al. Lyophilized cheliensisin A submicron emulsion for intravenous injection: characterization, in vitro and in vivo antitumor effect [J]. IntJPharm, 2008, 357(122): 139-142.
  • 5Liu Y, Lin X, Tang X. Lipid emulsions as a potential delivery system for ocular use of azithromycin [J]. Drug Dev IndPharm, 2009, 35(7): 887-896.
  • 6Mandawgade S D, Sharma S, Pathak S, et al Development of SMEDDS using natural lipophile Application to β-artemether delivery [J]. Int J Pharm 2008, 362(1/2): 179-183.
  • 7Yue P F, Yuan H L, Li X Y, et al. Development and optimization of intravenous puerarin emulsions formation by a novel complex-phase inversion-homogenization technology [J]. Chem Pharm Bull, 2007, 55(11): 1563- 1568.
  • 8Yeeprae W, Kawakami S, Higuchi Y, et al. Biodistribution characteristics of mannosylated and fucosylated O/W emulsions in mice [J]. JDrug Target, 2005, 13(8/9): 479- 487.
  • 9Tamilvanan S, Schmidt S, Muller R H, et al. In vitro adsorption of plasma proteins onto the surface (charges) modified-submicron emulsions for intravenous administravtion [J]. Eur J Pharm Biopharm, 2005, 59(1): 1-7.
  • 10Seok M K, Hae Y N, Taehwan N, et al. In vivo time-dependent gene expression of cationic lipid-based emulsion as a stable and biocompatible non-viral gene carrier [J]. J Controlled Release, 2008, 128(1): 89-97.

引证文献1

二级引证文献6

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部